Catalent, Inc. (CTLT)

NYSE: CTLT · IEX Real-Time Price · USD
55.98
+1.26 (2.30%)
Feb 2, 2023, 9:47 AM EST - Market open
2.3%
Market Cap 10.07B
Revenue (ttm) 4.83B
Net Income (ttm) 421.00M
Shares Out 179.96M
EPS (ttm) 2.35
PE Ratio 23.29
Forward PE 13.19
Dividend n/a
Ex-Dividend Date n/a
Volume 177,806
Open 54.03
Previous Close 54.72
Day's Range 55.35 - 56.69
52-Week Range 40.69 - 115.34
Beta 1.23
Analysts Buy
Price Target 70.89 (+26.64%)
Earnings Date Feb 7, 2023

About CTLT

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary ... [Read more]

Sector Healthcare
IPO Date Jul 31, 2014
Employees 19,000
Stock Exchange NYSE
Ticker Symbol CTLT
Full Company Profile

Financial Performance

In 2022, Catalent's revenue was $4.83 billion, an increase of 20.76% compared to the previous year's $4.00 billion. Earnings were $503.00 million, a decrease of -4.91%.

Financial Statements

Analyst Forecast

According to 22 analysts, the average rating for CTLT stock is "Buy." The 12-month stock price forecast is $70.89, which is an increase of 26.64% from the latest price.

Price Target
$70.89
(26.64% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Catalent (CTLT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Catalent (CTLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 day ago - Zacks Investment Research

Catalent, Inc. Announces Second Quarter Fiscal Year 2023 Earnings Conference Webcast

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patien...

1 week ago - Business Wire

Catalent Appoints Ricardo Zayas as North American Biologics Operations Leader

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced the appointment of Ricard...

2 weeks ago - Business Wire

Catalent's (CTLT) New Deal to Utilize Its Zydis ODT Technology

Catalent's (CTLT) latest development and license agreement is expected to accelerate the administration of therapeutic doses of active drugs.

2 weeks ago - Zacks Investment Research

Avantor® and Catalent Enter into Multi-Year Supply and Services Agreement

RADNOR, Pa. and SOMERSET, N.J.

Other symbols: AVTR
3 weeks ago - PRNewsWire

Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate

SOMERSET, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, and Sarepta Therapeutic...

Other symbols: SRPT
1 month ago - Business Wire

Catalent, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patien...

1 month ago - Business Wire

These 20 stocks were the biggest losers of 2022

This has been the year of reckoning for Big Tech stocks — even those of companies that have continued to grow sales by double digits.

1 month ago - Market Watch

Catalent Announces Changes to its Board of Directors

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patien...

1 month ago - Business Wire

Catalent (CTLT) Expands Facility Capabilities in Shanghai

Catalent's (CTLT) latest capability expansion is expected to boost its business in the clinical trials space in its Asia-Pacific Clinical Supply Services network.

2 months ago - Zacks Investment Research

Bear Of The Day: Catalent (CTLT)

Earnings estimates have slipped for this stock following the most recent earnings miss.

2 months ago - Zacks Investment Research

After a $100 Haircut, is Catalent an Oversold Pharma Play?

With the macro backdrop weakening for Catalent's pharmaceutical and biotech customers, fundamental concerns could outweigh what the charts suggest.

2 months ago - MarketBeat

Catalent stock paces S&P 500 losers as it suffers record selloff after earnings miss, lowered outlook

Shares of Catalent Inc. CTLT, -23.31% plunged 23.4% toward a record one-day selloff, and enough to pace the S&P 500's SPX, -0.35% losers, after the contract drug manufacturing company reported fiscal ...

3 months ago - Market Watch

Catalent (CTLT) Q1 Earnings Lag Estimates, FY23 View Cut

Catalent (CTLT) records robust first-quarter fiscal 2023 results of its Pharma and Consumer Health segment despite overall soft performance.

3 months ago - Zacks Investment Research

Why Is Catalent (CTLT) Stock Down 24% Today?

Catalent (NYSE: CTLT) stock is falling hard on Tuesday as investors react to dismal results in its earnings report for the fiscal first quarter of 2023. The bad news for investors in CTLT stock start...

3 months ago - InvestorPlace

Catalent (CTLT) Q1 Earnings and Revenues Miss Estimates

Catalent (CTLT) delivered earnings and revenue surprises of -38.18% and 4.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Catalent, Inc. Reports First Quarter Fiscal 2023 Results

SOMERSET, N.J.

3 months ago - Business Wire

Analysts Estimate Catalent (CTLT) to Report a Decline in Earnings: What to Look Out for

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

New Strong Sell Stocks for October 14th

AHEXY, BLWYY, and CTLT have been added to the Zacks Rank #5 (Strong Sell) List on October 14, 2022.

3 months ago - Zacks Investment Research

Jim Cramer goes over the best and worst Q3 performers in the S&P 500

Cramer said he wouldn't touch this stock with a 10 foot pole.

4 months ago - CNBC

JAZZ vs. CTLT: Which Stock Is the Better Value Option?

JAZZ vs. CTLT: Which Stock Is the Better Value Option?

Other symbols: JAZZ
4 months ago - Zacks Investment Research

The 5 Best—and 5 Worst—S&P 500 Stocks in the Third Quarter

The market has had a terrible run. Barron's takes a look at the winners and losers this quarter.

4 months ago - Barrons